About
Products
Knolens
KnolScapes
Knolens
Knolens SLR
Knolens
KnolQuest
Knolens
Edge
Knolens
DataNexus
Platform
Solutions
KnolSights
Experience Knolens
OBI Pharma's OBI-902 IND Application Cleared for Phase 1/2 Trial in Advanced Solid Tumors
OBI Pharma announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OBI-902, a Trop-2...
Copyright © 2025. All rights reserved
About
Terms of Service
Privacy Policy
Home/
KnloSights/
Clinical Trial Updates/
OBI Pharma's OBI-902 IND Application Cleared for Phase 1/2 Trial in Advanced Solid Tumors